US FDA grants fast track designation to NKGen Biotech’s natural killer cell therapy, troculeucel to treat moderate Alzheimer’s disease: Santa Ana, California Saturday, Februar ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

Researchers say study provides sufficient rationale to further explore the therapeutic uses of SSRIs during infection.

Police have arrested six suspects, recovered some stolen items, and are investigating potential thefts. They also found that ...

Vistagen Therapeutics, Inc.'s fasedienol shows promise in treating social anxiety; new results expected 2025. Click for my ...

EXPLORE Health Money Travel Food Style Book Club Classifieds #ZoomerDaily Policy & Perspective Arts & Entertainment Stars & ...

TORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company ...

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

A biotech company is attempting to persuade Kansas legislators to modify the state’s controlled substances act in advance of ...

A recent drug discovery could eventually help the visually impaired and those suffering from multiple sclerosis, traumatic stroke, and Alzheimer’s disease regain some of their vision and mental ...

Corbus Pharmaceuticals presented Phase 1 data on CRB-701 at ASCO GU, showing safety, tolerability, and responses across multiple tumor types.